Zheng Li usually goes to the public experimental area in the morning to listen to everyone's questions and offer some ideas.
Then he returned to the 17th floor, where he was all alone. The 17th floor contained only different kinds of experimental animals besides him.
The most commonly used biological experimental animals are mice, and some other common ones include macaques, chimpanzees, dogs, rabbits, etc.
Cows and sheep are relatively rare in experiments, but sheep are the most famous; the first cloned animal was Dolly the sheep.
Zheng Li's laboratory has the largest number of mice and the largest area occupied by macaques.
With the rapid growth of domestic biopharmaceutical research and development and the continuous improvement of domestic new drug safety evaluation requirements, the number of monkeys required for preclinical research is increasing year by year.
In addition, due to their high genetic homology with humans, laboratory monkeys are highly susceptible to epidemics, making them the most effective experimental animal subjects after an outbreak.
The price of laboratory monkeys has skyrocketed, rising from 60,000 yuan per monkey at the beginning of the year to nearly 100,000 yuan per monkey now in China.
In Singapore, it's even more expensive; a single laboratory monkey typically costs 120,000.
In the previous verification phase, mice were used to implant the most basic magic brain into their bodies. This most basic magic brain can only enable organisms to influence reality through instinct, but it cannot accurately turn what you want to do into reality.
Just like you can't achieve the level 0 Trick Hand in the D&D system using the most basic magic brain.
From its inception, the monk believed in the existence of the soul, which later evolved into the belief that all intelligent life forms possess a soul.
However, for a long time, the monks were unable to verify this view, just as humans in the past believed in the existence of gods but were unable to verify it.
As times progressed, sorcerers directly observed the existence of the soul through research.
Later, the monks discovered that memory, soul, and body are the components of intelligent life.
To use a computer system familiar to Earth, the body is the hardware, the soul is the middleware, and memory is the system and software.
This groundbreaking discovery came after mages researched spatial teleportation. They found that while teleporting objects was possible, if the object being teleported was an intelligent being, it would only act on instinct after being teleported.
The mage then strongly suspected that the teleportation caused intelligent beings to lose their souls, a claim that was later successfully proven.
Even by the time Zheng Li arrived on Earth, the mage still hadn't figured out a way to transfer the soul, body, and memories together.
Soul, memory, and body are like an impossible triangle; when a spatial jump occurs, only two of the three can exist.
In other words, in transmigration novels set on Earth, soul transmigration is possible, but physical transmigration is impossible.
Furthermore, the degree of compatibility between the soul and the magic brain is directly related to the spellcasting ability. The Mage Alliance will provide standard magic brains, but some people will choose to have their magic brains customized by specialized institutions.
Zheng Li needed to experiment with monkeys because monkeys are also intelligent beings, and they also have souls.
To find a match between the artificial brain and the soul, he needs to conduct experiments on experimental monkeys.
The research and development of the artificial brain is lengthy and tiring, but fortunately, there are accurate goals and sound theoretical support, so that people do not lose confidence and fighting spirit.
(The specific experimental steps are a bit disgusting, so I won't write them out. I was already disgusted with myself after writing 500 words, so I'll just leave it at that.)
Simply put, it involves implanting an embryo-like demonic brain into the embryo inside a mother monkey, removing the embryo that is not yet fully formed but already has a soul, and then using a specific device to observe its compatibility.
Finally, the embryos are processed.
......
At the beginning of 2021, a year had passed since the outbreak of the epidemic, and the epidemic had not improved at all. To be precise, it had not improved worldwide, but had instead intensified.
Global demand for endorphins continues to grow. Previously, Kechuang Bio's technology licensing period was five years, and even after licensing to other companies, endorphins were still in short supply.
Because alpha-endorphins reduce the addictive effects of opioids, the purchase of endorphins has increased significantly. MDI has taken the lead in announcing that it will provide endorphins free of charge to addicts to reduce their addiction to drugs.
As some European countries and Australia followed suit, the demand for endorphins further increased.
Because endorphins need to work together with lipoprotein trypsin peptides to reduce addiction, the demand for lipoprotein trypsin peptides has been increasing.
The management of Kechuang Bio did not want to see the market dominated by other authorized pharmaceutical companies, so they also wanted to expand the production of endorphins.
The annual output of endorphins at the Suzhou production base is now about L, which is double that of the middle of the year.
After the Lion City R&D Center was put into use, the money on Kechuang Bio's books was spent like water.
The minority shareholders of Kechuang Bio hope that the company will start the next round of venture capital, while the management of Kechuang Bio hopes to go public directly.
They can only obtain stock options and achieve financial freedom if Kechuang Bio goes public. It is highly unlikely that Kechuang Bio's Series C venture capital will provide a dedicated option pool for management.
Zheng Li did not want to further dilute his shares in Kechuang Biotechnology. If another round of venture capital were to be launched, his equity stake would likely drop to less than 50% by the time the company went public.
The drop to below 50% means that science and technology innovation is no longer his sole domain. If the Demon Brain makes no progress, his life will probably not be as good as it is now.
“If we’re going to go public, it would be best to list on the A-share market. Listing on the US stock market in the current situation might not be a good thing,” Li Miaomiao said.
Zheng Li nodded: "You guys discuss these things first, come up with a plan, and then report back to me."
After Kechuang Bio announced its intention to go public, major securities firms flocked to its doors.
To put it simply, a total of 145 companies were listed on the Science and Technology Innovation Board in 2020, raising a total of RMB 222.622 billion.
The valuation of Kechuang Bio is approximately 120 billion US dollars, and the funds raised will be at least 72 billion RMB.
This is because the Science and Technology Innovation Board (STAR Market) requires the issuance of at least 10% of its shares.
Since its listing in China, Kechuang Bio has been hailed as China's largest unicorn company. The purpose of this listing is to expand the production scale of endorphins.
This is a sure-fire way for securities firms to make money. For their investment banking departments, this deal with the science and technology innovation sector alone can meet their annual performance targets.
What could be more satisfying than completing the year's marketing goals at the beginning of the year?
Besides CITIC Securities and CITIC Construction Investment, Suzhou-based Dongwu Securities is the most active.
Smaller securities firms generally don't have a chance with an IPO of this size, but Dongwu Securities is trying to swallow a giant by taking advantage of its headquarters in Suzhou.
Continue read on readnovelmtl.com
